Anika Therapeutics (ANIK) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.51 +0.34%
EPS Growth %: +950.0%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
OMID, BCML, CZNC, More
EPS Growth %: +950.0%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.46, $0.01 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $27.2 million versus the consensus estimate of $28.92 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- Wabtec (WAB) Tops Q3 EPS by 10c; raises guidance
- Moody's Corp. (MCO) Misses Q3 EPS by 11c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
